scholarly journals Anterior Mediastinal Mass in a Young Marijuana Smoker: A Rare Case of Small-Cell Lung Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Jiten P. Kothadia ◽  
Saurabh Chhabra ◽  
Alan Marcus ◽  
Michael May ◽  
Biren Saraiya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rare Case ◽  
Mediastinal Mass ◽  
Vena Cava ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Anterior Mediastinal Mass ◽  
Small Cell Lung

The use of cannabis is embedded within many societies, mostly used by the young and widely perceived to be safe. Increasing concern regarding the potential for cannabis to cause mental health effects has dominated cannabis research, and the potential adverse respiratory effects have received relatively little attention. We report a rare case of 22-year-old man who presented with bilateral neck lymphadenopathy, fatigue, and sore throat without significant medical or family history. The patient had smoked one marijuana joint three times a week for three years but no cigarettes. Chest CT demonstrated a large anterior mediastinal mass compressing the superior vena cava and mediastinal lymphadenopathy. A final diagnosis of small-cell lung cancer was reached. Although rare, a small-cell lung cancer in this patient should alert the physician that cannabis smoking may be a risk factor for lung cancer.

scholarly journals Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report

2017 ◽  
Vol 10 (1) ◽  
pp. 252-257 ◽  
Author(s):  
Christina Brzezniak ◽  
Bryan Oronsky ◽  
Corey A. Carter ◽  
Bennett Thilagar ◽  
Scott Caroen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Superior Vena Cava ◽  
Cell Lung Cancer ◽  
Superior Vena ◽  
Vena Cava ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Svc Syndrome

Superior vena cava (SVC) syndrome, a potential oncologic emergency, is closely associated with malignancy and right-sided lung cancer in particular. A case of SVC syndrome presenting with facial swelling, neck distension, and enlarged veins of the upper chest, which developed over a period of 5 weeks in a 46-year-old patient on a clinical trial with small-cell lung cancer, is reported. Computed tomography scan of the chest revealed slight enlargement of a superior conglomerate mediastinal lymphadenopathy and intramural thrombus of the SVC. The etiology, diagnosis, and treatment of the SVC syndrome are discussed.

scholarly journals A Gastric Lesion Revealing a Small-Cell Lung Cancer: A Rare Case

2021 ◽  
pp. 1-3
Author(s):  
Miguel Mascarenhas Saraiva ◽  
Tiago Ribeiro ◽  
Francisco Moreira ◽  
Joanne Lopes ◽  
Amadeu Corte Real ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rare Case ◽  
Gastric Lesion ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals A Rare Case of ROS1 and ALK Double Rearranged Non–Small Cell Lung Cancer

2017 ◽  
Vol 12 (6) ◽  
pp. e71-e72 ◽  
Author(s):  
Arnaud Uguen ◽  
Ulrike Schick ◽  
Gilles Quéré
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rare Case ◽  
Small Cell ◽  
Small Cell Lung

Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report

Chemotherapy ◽  
2018 ◽  
Vol 63 (5) ◽  
pp. 257-261
Author(s):  
Masahiro Yamasaki ◽  
Kunihiko Funaishi ◽  
Naomi Saito ◽  
Ken-ichi Sakamoto ◽  
Sayaka Ishiyama ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mycobacterium Avium ◽  
Cell Lung Cancer ◽  
Left Lung ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Before And After ◽  
Avium Infection

Background: Small-cell lung cancer (SCLC) rarely coexists with pulmonary Mycobacterium avium intracellular complex (MAC) infection. The key drug for SCLC treatment is etoposide, which is metabolized by cytochrome P-450 (CYP) 3A4. Meanwhile, the key drugs for pulmonary MAC infection are clarithromycin (CAM) and rifampicin (RFP), and their metabolism influences CYP3A4. Therefore, treatment of concurrent SCLC and pulmonary MAC infection is difficult, and to the best of our knowledge, no report of treatments for concurrent SCLC and pulmonary MAC infection has been published. Patient Concerns and Diagnoses: A 65-year-old man presented to our hospital with abnormal findings of chest computed tomography: (1) a hilar region nodule in the left lung and mediastinal lymphadenopathy and (2) a thick-walled cavity lesion in the right upper lobe of the lung. After further examinations, the former lesions were diagnosed as SCLC, cT4N3M0, stage IIIC and the latter as pulmonary MAC infection, fibrocavitary disease. Interventions and Outcomes: Concurrent treatment was conducted with discontinuation of CAM and RFP before and after etoposide administration. Specifically, intravenous cisplatin and etoposide were administered on day 1 and days 1–3, respectively, and CAM, RFP, and ethambutol (EB) were administered orally on days 6–22 every 4 weeks. Concurrent radiotherapy was added to the drug administration on days 1–27 of the first cycle. The chemotherapy was continued for 4 cycles, followed by continuation of CAM and RFP administration. EB was discontinued because of optic nerve disorder. The treatments were conducted completely and safely, and both of the SCLC lesions and the MAC lesion were improved. Conclusions: Treatments for concurrent SCLC and pulmonary MAC infection may be successfully conducted with discontinuation of CAM and RFP before and after etoposide administration.

Usefulness of CT Chest in Determining Clinically Significant Mediastinal Lymphadenopathy in Patients With Non-Small Cell Lung Cancer (NSCLC)

CHEST Journal ◽  
2003 ◽  
Vol 124 (4) ◽  
pp. 194S
Author(s):  
Mazen Alakhras ◽  
Geetha Kanajam ◽  
Damodhar Nerella ◽  
Karthikeyan Kanagarajan ◽  
Depakkumar Malli ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Clinically Significant

scholarly journals Intramedullary thoracic spinal metastasis from small-cell lung cancer

2013 ◽  
Vol 79 (3-4) ◽  
Author(s):  
S. Katsenos ◽  
M. Nikolopoulou
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Spinal Metastasis ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord ◽  
Thoracic Spinal

Intramedullary thoracic spinal metastasis from small-cell lung cancer. S. Katsenos, M. Nikolopoulou. Lung cancer with intramedullary spinal cord metastasis (ISCM) is a rare event exhibiting dismal prognosis. In the present paper, we describe a 74-year-old male who developed bilateral leg weakness with associated backache and non-productive cough. Chest imaging evaluation demonstrated pronounced bilateral mediastinal lymphadenopathy and a nodular opacity in the right lower lobe. The patient was diagnosed with small cell lung cancer through bronchoscopic procedures. Magnetic resonance imaging of the spinal cord with contrast-enhancement revealed an intramedullary lesion consistent with metastasis at the T5-T6 level. Despite chemotherapy and thoracic spine radiotherapy, he eventually succumbed to the disease 3 months after diagnosis. A brief overview of the current literature is also provided laying emphasis on the therapeutic strategies of this unusual extrathoracic metastatic disease.

Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.

1990 ◽  
Vol 8 (3) ◽  
pp. 390-395 ◽  
Author(s):  
W K Evans ◽  
E A Eisenhauer ◽  
Y Cormier ◽  
J Ayoub ◽  
R Wierzbicki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Trial Design ◽  
Eastern Cooperative Oncology Group ◽  
Vena Cava ◽  
Small Cell ◽  
New Drugs ◽  
Small Cell Lung ◽  
Investigational Agent

Thirteen previously untreated patients with extensive small-cell lung cancer (SCLC) were treated with the investigational agent amonafide in a dose of 300 mg/m2 intravenously (IV) over 1 hour daily for 5 consecutive days. No responses were seen in 12 eligible patients. Myelosuppression was only occasionally seen. Other toxicities included diaphoresis, chest pain, local irritation at the injection site, arthralgias, nausea and vomiting, and neuromuscular problems. There were two early deaths, both attributable to tumor progression with resultant obstruction of a vital structure. Ten patients crossed over to alternate active therapy (etoposide [VP-16]-cisplatin) and five responded. The median survival time (MST) of the whole group of treated patients was 31 weeks. In future trials of investigational new drugs in previously untreated SCLC, we recommend that patients with the following characteristics be excluded: Eastern Cooperative Oncology Group (ECOG) performance status 2, 3, and 4; superior vena cava (SVC) obstruction; any major paraneoplastic syndrome; serious comorbid illness; and extensive hepatic involvement by tumor. The trial design should include prompt crossover to active alternative therapy, such as VP-16 and cisplatin, for disease progression or for failure to respond after two treatment cycles. Also, the trial design should use an early stopping rule based on interest in identifying only very active agents with a minimum response rate of 30%.

A RARE CASE OF PARANEOPLASTIC EDEMATOUS DERMATOMYOSITIS ASSOCIATED WITH SMALL CELL LUNG CANCER

CHEST Journal ◽  
2019 ◽  
Vol 156 (4) ◽  
pp. A274
Author(s):  
Ly Tran ◽  
Jeremy Harvey ◽  
Mathew Thomas ◽  
James Davidson ◽  
Rahul Sampath
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rare Case ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals A Rare Case of Non-Small Cell Lung Cancer with BRAF V600E Gene: Case Report and Literature Review

Cureus ◽  
2020 ◽  
Author(s):  
Dharti Patel ◽  
Ateeq Mubarik ◽  
Shilen Patel ◽  
Ali Vaziri ◽  
Salman Muddassir
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Literature Review ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rare Case ◽  
Small Cell ◽  
Braf V600e ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document